Salivary proteomics has identified molecular patterns associated with relapsing-remitting multiple sclerosis (RRMS) and changes occurring during disease-modifying therapy, suggesting that saliva could provide a noninvasive sample for studying molecular changes over time.
The exploratory study compared saliva samples from 66 patients with RRMS before starting a new therapy with samples from 31 healthy controls. 40 patients provided a second sample after six months of treatment.
Researchers from the University of Cagliari and collaborating institutions analyzed the samples using nano-liquid chromatography coupled with high-resolution tandem mass spectrometry. The workflow used an LTQ Orbitrap Elite instrument and label-free quantification based on precursor-ion areas.
The analysis identified 1,305 proteins after contaminants were removed. Of these, 623 met the criteria for statistical analysis, and 209 differed significantly across the main comparisons.
Before treatment, 116 proteins differed in abundance between patients with RRMS and healthy controls. After six months of therapy, 54 proteins remained different between the patient and control groups. The researchers interpreted this reduction as evidence of changing salivary protein patterns, rather than proof of treatment response.
Further analysis identified several types of molecular pattern. 28 proteins remained altered at both patient time points, indicating persistent RRMS-associated differences. Another 38 shifted toward the levels observed in healthy controls after six months, while 25 became significantly different only at follow-up. Paired analysis also detected 36 proteins that changed within individual patients but did not differ significantly from controls at either time point.
Pathway enrichment linked many of the altered proteins to innate immunity, neutrophil degranulation, cytokine signaling, programmed cell death, and protein folding. Proteins associated with inflammatory pathways moved toward control levels after treatment.
The researchers also identified a 50-protein panel that distinguished healthy controls, patients before treatment, and patients after six months of therapy within the study cohort.
The authors therefore caution that the protein panel is not ready for diagnostic or clinical use. Its current value lies in identifying candidate markers and demonstrating an analytical strategy for monitoring molecular changes through repeated, noninvasive sampling. Larger multicenter studies will need to compare salivary signatures with clinical findings, imaging, and established fluid biomarkers.
